drugset
drugset / Trial / NCT05765851

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

NCT05765851 ↗

Phase 1 Recruiting 108 enrolled Daiichi Sankyo AstraZeneca · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This study will evaluate the safety and efficacy of DS-1103a combination therapy in participants with advanced solid tumors.

Timeline

Start
2023-05-30
Primary completion
2030-05-15
Completion
2030-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject DS-1103a Monoclonal antibody 100 mg Intravenous
Background T-DXd Unknown — Intravenous

Indications

neoplasm